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Abstract
Background: Nicotine replacement therapies (NRT) and a new drug, bupropion, are licensed in
several countries as aids to smoking cessation. General practitioners (GPs) play a crucial role in
recommending or prescribing these medications. In the UK there has been discussion about
whether the medications should be reimbursable by the National Health Service (NHS). This study
assessed English GPs' attitudes towards reimbursement of NRT and bupropion.
Methods: Postal survey of a randomly selected national sample of GPs; 376 GPs completed the
questionnaire after one reminder; effective response rate: 53%. There was no difference between
the responses of GPs who responded to the initial request and those who responded only after a
reminder suggesting minimal bias due to non-response.
Results: Attitudes of GPs were remarkably divided on most issues relating to the medications.
Forty-three percent thought that bupropion should not be on NHS prescription while 42% thought
that it should be (15% did not know); Fifty percent thought that NRT should not be on NHS
prescription while 42% thought it should be (8% did not know). Requiring that smokers attend
behavioural support programmes to be eligible to receive the medications on NHS prescription
made no appreciable difference to the GPs' views. GPs were similarly divided on whether having
the medications reimbursable would add unacceptably to their workload or offer a welcome
opportunity to discuss smoking with their patients. A principal components analysis of responses
to the individual questions on NRT and bupropion revealed that GPs' attitudes could be
understood in terms of a single 'pro-con' dimension accounting for 53% of the total variance which
made no distinction between the two medications.
Conclusions: GPs in England appear to be divided in their attitudes to medications to aid smoking
cessation and appear not to discriminate in their views between different types of medication or
different aspects of their use. This suggests that their attitudes are generated by quite fundamental
values. Addressing these values may be important in encouraging GPs to adhere more closely to
national and international guidelines.
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Background
The causal link between smoking and increased morbid-
ity and mortality is firmly established; 3 million people
globally are estimated to die each year as a result of
smoking [1]; about half of these die in middle age or be-
fore [2]. Smokers are less fit than non-smokers, they suf-
fer more from both minor and major illness, and they feel
less healthy [3].
Nicotine replacement therapy (NRT) [4] and bupropion
(Zyban) [5,6] are both effective aids to smoking cessa-
tion. In the UK, from April 2001, bupropion joined NRT
as an approved medication for the treatment of nicotine
dependence and both are now available on NHS pre-
scription. Both medications are also available to smokers
wanting to quit in the United States of America, Austral-
ia, New Zealand and France.
In the UK General Practitioners (GPs) have an important
role in recommending or prescribing stop smoking med-
ications. The English National Smoking Cessation
Guidelines [7] recommended that GPs should recom-
mend, provide accurate information on and prescribe
NRT or bupropion. US guidelines and new European
guidelines also place considerable emphasis on the use
by GPs and other health professionals of NRT and bupro-
pion [8].
General practice is a key area in which the battle to re-
duce smoking prevalence in the UK will be won or lost;
99% of the population are registered with a GP [9] and
about 80% of people consult with their GP at least once a
year [10], the figure being even higher for smokers [11].
The evidence indicates that brief firm advice to stop
smoking given by a GP to all known smokers, whether or
not they want to stop, can lead to an increase in long-
term (at least 12 month) cessation rates of about 1–2%
[12].
However, a survey conducted in 1993 found that only
29% of smokers who had seen their GP in the previous 12
months said they had been given advice on smoking [13].
Previous studies have also indicated that interventions
that are known to be cost-effective as a means of promot-
ing smoking cessation are not being routinely imple-
mented [13–15]. Depending upon GPs' views, the
provision of NRT and bupropion on NHS prescription
may prompt smoking cessation interventions.
When this survey was conducted (March to June 2000)
most forms of NRT were on the NHS prescription black-
list, thus for most people NRT had to be obtained over-
the-counter or on a private prescription. Bupropion was
still to be approved by the Medicines Control Agency and
there was debate as to whether it should be available on
the NHS or whether patients should have to pay for it.
This survey was conducted to assess GPs' attitudes to-
wards NRT and bupropion being available on NHS pre-
scription and whether such a prescription should only be
issued if patients are willing to receive behavioural sup-
port or counselling. GPs were also asked how helpful
NRT and bupropion being available on prescription
would be in raising the topic of smoking cessation with
patients, whether this would add unacceptably to their
workload and if it was an appropriate use of NHS re-
sources. Information on the gender, smoking status and
age of all respondents was collected. GPs were also asked
where their practice was situated, including a question
about whether any of their patients lived in a 'Health Ac-
tion Zone' (HAZ), and whether they worked alone or in a
group practice. HAZs are areas of deprivation with iden-
tified local health needs whose health service providers
receive additional funding from the Department of
Health. About a quarter of the English population live in
HAZs. The availability of funding to develop smoking
cessation services in HAZs occurred in 1999, a year prior
to other health authorities.
Sample and methods
This was a postal survey of a random sample of GPs in
England and Wales conducted between March and June
2000. A National Department of Health GP database
was used to generate the sample. This database is updat-
ed every three months. Random numbers were used to
generate 1003 names and addresses from the total pop-
ulation. There were 726 usable names and addresses of
individual GPs. Questionnaires were sent to this sample
and 247 were completed and returned. In 17 further cas-
es the questionnaire was returned uncompleted because
the GP had moved away. A second mailing was sent to
the non-responders four weeks later which yielded a fur-
ther 128 responses and 8 uncompleted questionnaires
returned because the GP had moved away. The 375 re-
spondents represented an absolute response rate of 52%
and the effective response rate based on those known to
have actually received the questionnaire was 53%.
Seventy-nine percent of respondents were male; the pro-
portion found among GPs nationally is 68%[16]. The age
distribution of respondents did not closely resemble the
national distribution with an over-representation of GPs
over 60 years of age [16]: (national figures are in brack-
ets): <30 = 1.9% (1.2%), 30–39 = 26% (33%), 40–49 =
18% (36%), 50–59 = 19% (23%) and >60 = 35% (6.2%).
National statistics reveal that 30% of GPs in England and
Wales work in single-handed practices and 70% in prac-
tices with more than one GP [17], compared with 11% and
89% respectively with our respondents. A total of 32.5%
of respondents in the sample reported that all or some of
their practice patients lived in health action zones; 22%BMC Family Practice 2001, 2:6 http://www.biomedcentral.com/1471-2296/2/6
reported that their practices were in rural locations, 18%
in inner city locations and 61% in "other urban" loca-
tions. Differences between the sample and the national
demographics appear to have resulted from an interac-
tion between the random number generation procedure
and the structure of the NHS database used (involving a
tendency which was not detected for older doctors to ap-
pear earlier in the database), and not bias in the types of
GPs responding to the questionnaire. Deviations from
the national demographics do not appear to have led to
biases in key responses (see Results section).
A 16-item questionnaire was designed to identify: atti-
tudes towards NRT and bupropion and demographic
characteristics. The questionnaire was accompanied by a
covering letter addressed to the doctor concerned and a
FREEPOST envelope in which to return it.
Results
No significant differences were found between responses
from the first and second wave of respondents suggest-
ing that bias as a result of non-response was minimal
[18].
Table 1 shows that opinion on whether bupropion should
be reimbursed on NHS prescription was divided with
42% saying it should and 43% saying it should not. Opin-
ion on the other questions was also divided although
slightly more GPs thought having bupropion available on
prescription would not add unacceptably to their work-
load than those that did.
The responses to the questions asked about the availabil-
ity of NRT on NHS prescription closely resembled the re-
sponses to the questions relating to bupropion. Opinion
was divided evenly although slightly more GPs thought
having NRT available on prescription would not add un-
acceptably to their workload than those that did (Table
2).
Table 1: Percentage of GPs responding to questions relating to the reimbursement of bupropion on NHS prescription
No Don't know Yes
1. Do you think that bupropion should be put on the prescription blacklist 
once it has been approved by the MCA?
42% (n = 154) 15% (n = 56) 43% (n = 155)
2. Do you think that bupropion should be available on NHS prescription to 
smokers, but only if they are also willing to receive behavioural support or 
counselling?
48% (n = 177) 11% (n = 41) 41% (n = 149)
3. Do you think that having bupropion available on NHS prescription would 
be useful in helping you to raise the topic of smoking with patients?
45% (n = 163) 8% (n = 30) 47% (n = 173)
4. Do you think that having bupropion available on NHS prescription would 
add unacceptably to your workload?
50% (n = 184) 13% (n = 49) 36% (n = 133)
5. Do you think that having bupropion available on NHS prescription would 
be an appropriate use of NHS resources
42% (n = 154) 13% (n = 47) 46% (n = 168)
Table 2: Percentage of GPs responding to questions relating to the provision of NRT on NHS prescription
6. Do you think that NRT should be taken off No 50% (n = 183) Don't know 8% (n = 30) Yes 42% (n = 154)
the prescription blacklist?
7. Do you think that NRT should be available on NHS prescription 
to smokers, but only if they are also willing to receive behavioural
51% (n = 188) 8% (n = 30) 40% (n = 148)
8. Do you think that having NRT available on NHS prescription 
would be useful in helping you to raise the topic of smoking with 
patients?
47% (n = 169) 7% (n = 26) 46%(n = 167)
9. Do you think that having NRT available on NHS prescription 
would add unacceptably to your workload?
52% (n = 187) 12% (n = 44) 36%(n = 130)
10. Do you think that having NRT available on NHS prescription 
would be an appropriate use of NHS resources?
43% (n = 156) 9% (n = 33) 48%(n = 172)BMC Family Practice 2001, 2:6 http://www.biomedcentral.com/1471-2296/2/6
A principal components analysis of responses to the 10
items on NRT and bupropion indicated that the GPs' re-
sponses to all the questions reflected a single underlying
attitudinal dimension. For this analysis the response 'No'
was coded as 1, 'Don't know' as 2, and 'Yes' as 3. The anal-
ysis revealed that a single component accounted for 53%
of total variance involving all the questions (a second
component only accounted for 16% and a third for 11%).
The presence of a single coherent underlying scale was
confirmed by a coefficient alpha, based on the 10 items
(five each for NRT and bupropion), of 0.90. To examine
specifically how far GPs' responses on NRT and bupropi-
on were associated with each other, the five NRT ratings
were totalled as were the five bupropion ratings and the
two totals were correlated. The pearson correlation was
0.78 (p < 001) indicating a very close association be-
tween attitudes to the two types of product.
Nearly a third (32%, n = 117) of respondents in the sam-
ple reported that all or some of their practice patients
lived in health action zones (HAZs). Those GPs working
within HAZs (33%, n = 37) were less likely than those
GPs not in HAZ's (46%, n = 116) to state that they
thought that bupropion should be put on the prescrip-
tion blacklist (chi-square = 7.402, p < 03); although they
were more likely to respond with a "don't know" (21%
against 13% respectively). Similarly GPs in HAZs (14%, n
= 16) were more likely to give a "don't know" response
than GPs not in HAZs (6%, n = 14; Chi-Squared = 7.282,
p < 03) to the question as to whether they thought NRT
should be taken off the prescription blacklist. HAZ GPs
(13%, n = 15) were also more likely to say that they "don't
know" whether NRT available on NHS prescription
would help raise the topic of smoking with patients than
non-HAZ GPs (5%, n = 11; Chi-Squared = 8.731, p,.02).
HAZ GPs (36%, n = 40) were less likely to think that bu-
propion should not be available on NHS prescription,
but only if patients are willing to receive behavioural
support or counselling, than GPs not working within
HAZs (53%, n = 134; Chi-Squared 9.786, p < 008). A par-
allel result was reported in relation to NRT with 57% (n
= 142) of GPs outside HAZ's reporting that NRT should
not be available on prescription, even if conditional upon
patients' willingness to receive support or counselling,
compared with 39% (n = 45) of HAZ GP's (Chi-Squared
= 15.217, p < 01).
More respondents were male (79%, n = 293) than the
proportion found among GPs nationally (68%) [9]. How-
ever, except that more male GPs (51%, n = 146) thought
bupropion should only be available on prescription if ac-
companied by behavioural support or counselling than
female GPs (36%, n = 29; p < 01), there were no associa-
tions between gender and attitudes towards bupropion
and NRT. Although the age distribution of respondents
did not closely resemble the national distribution, with
an over-representation of GPs over 60 years of age, there
was no evidence of associations between age and atti-
tudes towards bupropion and NRT. An apparent under
representation of single-handed GP practices in this sur-
vey did not reveal any bias as no significant difference
between single-handed and group-practice GPs were
found. There were also no evidence of associations be-
tween where practices were situated (rural, inner city or
other urban locations) and attitudes towards the availa-
bility of NRT and bupropion on NHS prescription.
Discussion
GPs were clearly divided in their attitudes to medications
to help people stop smoking. Moreover they appeared to
make little distinction between types of medication and
their attitudes reflect a single 'pro-con' dimension. Previ-
ous surveys have revealed that most English GPs have
not accepted that NRT is worth the cost even though the
evidence indicates that in fact it is more than 10 times
more cost effective as a life-preserving intervention and
the average for medicine generally [19–21]. Our results
suggest that a similar view may prevail for bupropion but
that both may reflect more general value judgements
about stop smoking medications and their place in the
GPs' armamentarium. Possible bases for this general val-
ue judgement are failure to accept that nicotine depend-
ence is a genuine medical disorder, lack of sympathy for
a condition that is seen as self-inflicted, low absolute ef-
ficacy rates for the medications or other factors. On the
face of it, it may seem difficult to reconcile our finding
with other research showing that in principle most GPs
accept that they have a role to play in smoking cessation
[19] and research is needed into this issue to determine
how best to encourage GPs to follow what national guide-
lines indicate is best practice. If it turns out that GPs are
basing prescribing decisions in this area to some degree
on personal values regarding smokers rather than the
specific costs and benefits to health of the medications,
this is clearly a matter for concern and attention would
need to be directed at how to address this.
Those GPs within HAZ's appeared to hold a more posi-
tive, or more accurately a less negative, attitude towards
NRT and bupropion. This may be as a result of the likeli-
hood of there being a larger proportion of smokers
amongst their patient population than in other health
authorities. Alternatively it may be that Stop Smoking
Services being established with HAZs at the time had, by
raising awareness of smoking cessation and by the provi-
sion of services, produced a positive change in the atti-
tudes of GPs.
Several factors may limit the generalisability of the find-
ings. First the response rate was only just over 50 perBMC Family Practice 2001, 2:6 http://www.biomedcentral.com/1471-2296/2/6
cent and it may be that respondents were more likely to
have strong views on the subject either way than non-re-
spondents. However, the absence of a difference in re-
sponses between those who responded initially and
those who only responded after a reminder lends some
confidence that those who responded did not differ sub-
stantially from those who did not [18]. We have previ-
ously found in surveys of smoking cessation attitudes of
GPs with response rates of 70 per cent that there was no
difference between respondents in each of three waves
lending further support to the view that non-response
bias is limited in this kind of research [19]. In addition,
even if the precise figures are incorrect the general con-
clusions about opinion being highly divided and being
based on a single attitude dimension would not be ex-
pected to change. Secondly, the sample that responded
was not representative of the GP population in a number
of respects. However, responses to key items did not dif-
fer as a function of those demographic factors so this is
unlikely to have affected the results. Thirdly, one might
expect that attitudes would change over time and one
would also expect attitudes in different countries to dif-
fer. However, we believe that it is useful for countries at
different stages in the development of smoking cessation
policies to be aware of the likelihood of substantial divi-
sions of opinion among GPs and that these may be based
on more fundamental values than a specific scrutiny of
the evidence on particular types of medication. Since the
survey was conducted NRT and Zyban have both been
approved for reimbursement under the NHS and it
would be interesting to see whether attitudes have
changed accordingly in a follow-up survey.
Conclusions
GPs in England appear to be divided in their attitudes to
medications to aid smoking cessation and appear not to
discriminate in their views between different types of
medication or different aspects of their use. This sug-
gests that their attitudes are generated by quite funda-
mental values. Addressing these values may be
important in encouraging GPs to adhere more closely to
national and international guidelines.
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